Key Findings:  Cannabinoids could be a precious resource for future treatment of both acute and chronic diseases. Considering specific cultivars containing different cannabinoid constituents, it might be possible to select the appropriate variety enriched of a specific class of compounds to be used for a specific disease. Moreover, if we consider that the treatment of most degenerative diseases is still far from achieving full success, the research on hemp and CBD extracts is strongly encouraged in order to have enough data for a rational clinical application.
Type of Study:  Meta-analysis
Study Result:  Positive
Study Location(s):  Italy
Year of Pub:  2018
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabidiolic Acid (CBD-a), Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG), Pharma THC, Pharma THC:CBD, Pharma CBD
Phytocannabinoid Source:  Not Applicable
Chemotype:  Chemotype I, Chemotype II, Chemotype III
Terpenes Studied:  ß-Caryophyllene, Myrcene
Receptors Studied:  CB1, CB2, GPCR 18, GPCR 55, TRPV1, TRPV2, PPARs
Ligands Studied:  Anti-inflammatory cytokines, Serotonin, Pro-inflammatory cytokines, Neurotransmitter (unspecified/other)